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Research criteria for Alzheimer’s disease recommend the use of biomarkers for diagnosis, but 
whether biomarkers improve the diagnosis in clinical routine has not been systematically assessed. 
Aim is to evaluate the evidence for use of medial temporal lobe atrophy (MTA) as biomarker for 
Alzheimer’s disease at the MCI stage in routine clinical practice, with an adapted version of the 5-
phase oncology framework for biomarker development. A literature review on visual assessment of 
MTA and hippocampal volumetry was conducted with other biomarkers addressed in parallel 
reviews. Ample evidence is available for Phase 1 (rationale for use) and Phase 2 (discriminative ability 
between diseased and control subjects). Phase 3 (early detection ability) is partly achieved: most 
evidence is derived from research cohorts or clinical populations with short follow-up but validation 
in clinical MCI cohorts is required. In phase 4, only the practical feasibility has been addressed for 









Biomarker assessment at the time of clinical dementia is important for differential diagnosis and 
thereby also for prognosis and potential treatment. New clinical criteria have introduced the use of 
biomarkers for the diagnosis of Alzheimer’s disease (Dubois et al., 2014, 2007; Jack et al., 2011a; 
McKhann et al., 2011). These criteria also recommend the use of biomarkers for the diagnosis of 
Alzheimer’s disease in non-demented subjects with mild cognitive impairment (MCI) (Albert et al., 
2011). Early diagnosis offers an opportunity for early intervention, improved guidance for caregivers 
and more accurate prognosis.  
 
Several biomarkers for Alzheimer’s disease have been developed; however, there is insufficient 
systematically addressed evidence to implement them for a diagnosis of Alzheimer’s disease at the 
MCI stage in routine clinical practice (Frisoni et al., 2011). To overcome a similar problem in the field 
of oncology, Pepe and colleagues (2001) suggested to systematize the investigation of cancer 
biomarkers based on a framework borrowed from drug development. A similar approach may boost 
the adoption of Alzheimer’s disease biomarkers in clinical practice. An effort has recently been 
launched to adapt the oncology framework to suit the current goal of diagnosis of Alzheimer’s 
disease at the MCI stage, as described in the accompanying summarizing paper (Frisoni et al., in this 
issue). The present study fulfills a specific part of this wider plan: the analysis of the available 
evidence for medial temporal lobe atrophy (MTA) on MRI in the context of this framework. The other 
studies from this effort assessed within the common framework the following biomarkers: episodic 
memory assessment (Cerami et al., in this issue), cerebrospinal fluid measures (Mattsson et al., in 
this issue), amyloid PET (Chiotis et al, in this issue), [18F]FDG-PET (Garibotto et al., in this issue), and 
[123I]-Ioflupane and [123I]-MIBG imaging (Sonni, et al., in this issue). 
 
In a research setting, there are three methods commonly used to assess atrophy of the medial 
temporal lobe: visual rating, manual volumetry and automated volumetry. In visual rating, atrophy is 
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assessed on an ordinal scale. The most widely adopted visual rating scale in research, used in more 
than 100 publications, is the five-point Scheltens scale which was developed over twenty years ago 
(Scheltens et al., 1992). MTA is visually assessed on coronal images taking into account the width of 
the choroid fissure, width of temporal horn and height of hippocampus. Although visual rating scales 
can be broadly applied to a range of imaging acquisition methods and performed by a trained 
radiologist, it is still only sparsely adopted in clinical practice (Gardeniers et al., 2015). In manual 
volumetry, hippocampal atrophy is quantified by drawing multiple regions of interest by an 
experienced rater on adjacent coronal MRI slices, typically 1-3 mm thick. This requires trained raters 
and is time-consuming. Several automated methods, which estimate volumes of structures by means 
of a computer algorithm, have been developed. Most of these algorithms involve an automated 
segmentation and classification of hippocampal tissue. Volume is then calculated as the sum of all 
voxels classified as hippocampal tissue. These techniques require specialist software and expertise, 
are also time-consuming and results can vary across scanners and acquisition protocols. Manual and 
automated volumetry are currently only used in research settings and not yet implemented for 
clinical use.  
 
In this paper, we will review evidence for the maturity of visual rating of MTA (vMTA) and 
hippocampal volume (HCV) as biomarkers for Alzheimer’s disease at the MCI stage, where evidence 
is interpreted under the light of an adapted version of the oncology framework (Pepe et al., 2001; 




2. Methods  
This review was performed with reference to the oncology framework (Pepe et al., 2001), which was 
adapted to the field of dementia, specifically to the aim of performing the diagnosis of sporadic 
Alzheimer’s disease at the MCI stage (Frisoni et al., in this issue). The lexicon of this framework is 
extensively described in Frisoni et al., in this issue, and is summarized in this section. Only sporadic, 
not familial Alzheimer’s disease, is considered. The standard reference for diagnosis was Alzheimer’s 
disease neuropathology or the development of incident Alzheimer’s dementia at follow-up.  
 
2.1 Glossary  
Alzheimer’s disease is defined as the presence of Alzheimer’s pathology consisting of cerebral 
amyloid plaques and tangles, supposedly leading to a pattern-specific neurodegeneration (medio-
temporal and temporo-parietal distribution). The term is thus independent of the clinical 
manifestation of the disease.  
Alzheimer’s dementia is the clinical syndrome featuring acquired and progressive cognitive 
impairment associated with functional disability as defined by the NINCDS-ADRDA criteria (McKhann 
et al., 1984). Notably, not all cases of clinically diagnosed Alzheimer’s dementia have Alzheimer’s 
disease pathology due to the imperfect accuracy of purely clinical criteria.  
Mild cognitive impairment (MCI) is used to indicate the clinical condition between normality and 
dementia in which patients experience acquired cognitive impairment of greater severity than 
expected by age, but no functional disability. This population includes cases with Alzheimer’s disease 
(about 50%), cases with other neurodegenerative pathologies (10-15%) and cases without a 
neurodegenerative disorder (35-40%) (Bennett et al., 2002; Jack et al., 2008b; Jansen et al., 2015; 
Rowe et al., 2010). The MCI cases with Alzheimer’s disease biomarker positivity are defined as 
Prodromal Alzheimer’s disease in the clinical criteria by Dubois et al. (2010). The focus of this review 
is the use of biomarkers in the MCI stage.  
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Non-Alzheimer neurodegenerative disease includes neurodegenerative disorders that are not 
primarily due to Alzheimer’s pathology. These belong to a large pathological spectrum including 
hippocampal sclerosis, frontotemporal lobar degeneration (FTLD), progressive supranuclear palsy, 
corticobasal degeneration, argyrophilic grain disease, Lewy body disease (LBD) and other alpha-
synucleinopathies such as multiple system atrophy.  
 
2.2 Conceptual framework 
The main phases of the present framework for the development of biomarkers for early diagnosis 
reflect the phases covered in the original oncology framework by Pepe et al. (2001) and in turn 
inspired by pharmaceuticals development. The shift of the reference methodological model from the 
field of oncology to that of dementia implies a shift of aims from screening to diagnosis, as the 
examined biomarkers are validated for use in the clinical population of MCI (Frisoni et al., in this 
issue; Boccardi et al., in this issue). The present review assesses the clinical validity of medial 
temporal lobe atrophy within a translated framework, consisting of five phases with a main aim and 
various sub-aims. These (sub-)aims and evidence reported are summarized in Table 1, together with 
the most pertinent references. There are five consecutive phases of development that should be 
completed before clinical use of the biomarker for prediction of Alzheimer’s disease at the MCI stage.  
Phase 1: Phase 1 studies are preclinical exploratory studies, in which the aim is to find leads for 
potential biomarkers by identifying characteristics specific to the disease, based on pathology 
findings, which could be detected with clinical tests. 
Phase 2: Evaluation of the biomarker’s ability to discriminate patients with Alzheimer’s disease from 
controls. Ideally, evidence is based on studies in which a diagnosis of Alzheimer’s disease is also 
supported by autopsy findings. Sub-aims of phase 2 focus on defining and optimizing the clinical 
assay allowing reliable discrimination between patients and controls (sub-aim 1), determining the 
relation between pathological measurement and biomarker measurement (sub-aim 2) and the 
assessment of possible differential effects of factors in patients and controls that may influence the 
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thresholds for positivity (sub-aims 3 and 4). Relevant factors can be for example age, apolipoprotein 
E ε 4 (APOE4) carrier status and educational attainment.  
Phase 3: Phase 3 studies consist of prospective longitudinal studies and the main aim is to assess the 
ability of the biomarker to detect the disease at the MCI stage by evaluating the biomarker’s ability 
to predict the development of incident Alzheimer’s dementia at follow-up. In other words, to 
distinguish MCI progressors from non-progressors. We included studies examining the biomarker at 
baseline in subjects with MCI and sufficiently long follow-up, ideally over three years. Second main 
aim is to fine-tune the threshold for positivity. Sub-aims are to assess the impact of covariates on the 
discriminatory ability of the biomarker in the MCI stage (sub-aim 1), to compare the usefulness of the 
biomarker in comparison to or in combination with other available biomarkers (sub-aims 2 and 3) 
and to determine a biomarker testing interval (sub-aim 4). 
Phase 4: Main aim of phase 4 is to estimate the accuracy and usefulness of the biomarker-based 
early diagnosis in real world patients. It consists of prospective diagnostic studies in which the 
biomarker is used for an early diagnosis of Alzheimer’s disease, affecting decision-making regarding 
patient management and treatment. Sub-aims are to assess the benefit of the biomarker-based early 
diagnosis (sub-aim 1) and the feasibility of the biomarker assessment (sub-aim 2), and provides 
preliminary evidence on impact on mortality, morbidity and costs (sub-aim 3), and undetected cases 
(sub-aim 4). 
Phase 5: Phase 5 studies aim to quantify the impact of the biomarker-based early diagnosis on 
clinically meaningful outcomes and costs. They consist of disease-control studies assessing the 
reduction in mortality, morbidity and disability allowed by the biomarker-based diagnosis. Sub-aims 
are to assess cost-effectiveness (sub-aim 1), evaluate compliance in different settings (sub-aim 2) and 
to compare different biomarker testing protocols (sub-aim 3). However, this phase can be properly 
carried out only in the context of an effective and accepted treatment available. For the Alzheimer’s 




2.3 Literature search, article selection and evidence evaluation 
References for this review were selected searching the PubMed/Medline database in June 2015. A 
different search algorithm was used for the aims of the 5-phases, each one comprising an aim-
specific key word string and a biomarker specific key-word string: “MTA” OR “medial temporal” OR 
“hippocamp*”. The aim-specific key word strings can be found in supplementary table 1. Only papers 
published in English were included. References were also selected on the basis of the authors’ 
personal knowledge and by screening references from retrieved articles. When aims were 
unequivocally achieved, a reference paper or review was selected by the authors. The final selection 
of articles was based on relevance to topics covered in this review, as judged by the authors.  
For all phases, available literature was assessed and used to evaluate whether each aim was 
considered as Achieved, Partly Achieved, presenting with Preliminary Evidence, or Not Achieved for 
vMTA and HCV. Results of this assessment are visualized in figure 1. Fully Achieved: scientific 
evidence is available and replicated in representative samples in studies without major 
methodological faults. Partly Achieved: scientific evidence is available but not yet sufficiently 
replicated, or samples are not representative, or other significant methodological limitations can be 
found in the available literature. Preliminary evidence: only preliminary evidence is available. Not 
Achieved: no evidence was found and no studies are known to be ongoing at the time of the writing 
of this review. 
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3. Evidence for clinical validity of medial temporal lobe atrophy on MRI 
3.1 Phase 1 – Pilot studies 
The aim of phase 1 studies is to find leads for potential biomarkers based on pathological findings.  
Alzheimer’s disease is characterized by extracellular amyloid beta depositions and intraneuronal or 
extraneuronal neurofibrillary changes, eventually leading to neuronal destruction. Autopsy studies 
have shown that these changes already start many years before the onset of clinical symptoms with 
early and prominent neurofibrillary tangles in medial temporal lobe structures (Braak and Braak, 
1996, 1991; Delacourte et al., 1999; Duyckaerts et al., 2009). These neuropathological changes in the 
medial temporal lobe are accompanied by atrophy, which can be visualized on structural MRI 
(Scheltens et al., 2002).  
The first aim can be considered Fully Achieved for vMTA and HCV.  
 
3.2 Phase 2 – Clinical assay development for clinical disease 
The purpose of the second phase is to find a clinical measurement based on the findings from phase 
1, which can be easily obtained and sufficiently distinguishes subjects with and without Alzheimer’s 
disease. Secondary aims in this phase are to optimize the procedures for performing the 
measurement, assess reproducibility, validate the measurement against pathological measurements 
and assess factors associated with the measurement in controls and diseased subjects.  
 
3.2.1 Phase 2, Primary aim: ability to distinguish patients from controls.  
The primary aim of phase 2 is to assess the ability of vMTA and HCV to distinguish patients with 
Alzheimer’s disease from healthy controls.  
Many case-control studies have evaluated the use of MTA in differentiating subjects with clinically 
diagnosed Alzheimer’s dementia from healthy controls, which have recently been reviewed (Frisoni 
et al., 2013). Average specificity of a visual read of MTA to distinguish clinical Alzheimer’s dementia 
from healthy controls is 79% (CI 75-83) with average-good sensitivity of 70% (CI 65-74). In a 
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pathology verified sample of young Alzheimer’s disease subjects (mean age 59), the sensitivity of 
vMTA was high (92%) with a specificity of 62% (Likeman et al., 2005). Specificities and sensitivities of 
manual hippocampal volumetry are on average 82% (CI 78-85) and 79% (76-82) respectively (Frisoni 
et al., 2013). Specificities and sensitivities for automated measurements of HCV are on average 81% 
(CI 77-85) and 72% (CI 67-77) respectively (Frisoni et al., 2013). The specificty and sensitivity of HCV 
for detecting Alzheimer’s disease were in a similar range in two neuropathological studies: 0.80-
0.87% and 0.75-0.82% (Barnes et al., 2006; Gosche et al., 2002). 
 
Although MTA reasonably well distinguishes subjects with dementia from healthy controls, it is less 
useful in the differential diagnosis of Alzheimer’s dementia. Atrophy of the medial temporal lobe and 
hippocampus is also seen in other neurodegenerative diseases, as well as in vascular dementia 
(Barnes et al., 2006; Bastos-Leite et al., 2007; de Souza et al., 2013; Galton et al., 2001; Harper et al., 
2014; Likeman et al., 2005; van de Pol et al., 2006b). 
 
The primary aim of phase 2 can be considered Fully Achieved for vMTA and HCV.  
 
3.2.2 Phase 2, Secondary aim 1: optimize procedures for biomarker assessment. 
The first secondary aim of phase 2 is to optimize procedures for measuring medial temporal lobe 
atrophy and to assess the reproducibility of this measurement.   
Visual rating of MTA is quick and easy and can be performed by any trained rater, usually a 
radiologist. In contrast to volumetric methods, vMTA is relatively independent of acquisition 
protocol. Merely a good quality anatomical scan is required, which is usually a T1-weighted MRI with 
coronal reconstructions, but can also be a high-resolution CT scan (Wattjes et al., 2009). The 
Scheltens scale has reasonable inter-rater agreement and reproducibility. A study shortly after the 
development of the scale reports inter-rater agreements with kappa values of 0.59-0.62 for 
dichotomized vMTA into present or absent (Scheltens et al., 1995). In more recent publications, the 
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inter-rater kappa is usually higher, up to 0.90 (Tolboom et al., 2010). This may be due to advances in 
imaging acquisition techniques with higher field strengths and better display methods or more 
experience of the raters. Several studies have shown that the reproducibility and accuracy of vMTA is 
higher when scoring is performed by trained investigators (Boutet et al., 2012; Cavallin et al., 2012b).  
 
Volumetric methods may be influenced by scanner type and acquisition protocol (Huppertz et al., 
2010; Jovicich et al., 2009; Nugent et al., 2013; Wonderlick et al., 2009). To increase uniformity of 
MRI acquisition methods between different sites, the Alzheimer’s Disease Neuroimaging Initiative 
(ADNI), developed a standardized protocol for MRI acquisition (Jack et al., 2008a). Although this 
sequence has been adopted by some scanner manufacturers, it is not yet widely implemented for 
clinical use. 
 
Over the years, various methods for manual segmentation of the hippocampus and medial temporal 
lobe have been developed (Konrad et al., 2009). Due to the complexity of the hippocampal region 
and different definitions of anatomical landmarks across research groups, manual volumetry has 
varying reproducibility rates. Recently, effort has been put into the development of a standardized 
method for manual segmentation of the hippocampus: the EADC-ADNI Harmonized Protocol (HarP) 
(Boccardi et al., 2015a). Compared to local protocols, using the harmonized protocol for hippocampal 
segmentation results in higher intra- and interrater agreement (Frisoni et al., 2015). Given the time-
consuming and expensive nature of manual outlining, automated volumetry has higher potential to 
be broadly used in clinical setting. Automated methods approach performance of manual outlining in 
distinguishing healthy controls, MCI and subjects with Alzheimer’s dementia (Frisoni et al., 2013; 
Shen et al., 2010). Several (semi-)automated algorithms have been developed for the automated 
measurement of hippocampal volume. Non-commercial, widely used in research, algorithms include 
FIRST (FMRIB’s integrated registration and segmentation tool, FSL) (Patenaude et al., 2011; Smith et 
al., 2004) and FreeSurfer (Fischl et al., 2002). Several commercially available algorithms have been 
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developed, such as Assessa® (IXICO) based on the LEAP algorithm (Wolz et al., 2010) and 
NeuroQuant® (CorTechs Labs). These various methods use different a priori anatomical information 
on the hippocampus, as well as different computational strategies for volume estimation and 
therefore also provide different volumes for same subjects (Guadalupe et al., 2014; Yu et al., 2014). 
Although steps towards the standardization of automated methods have been undertaken (Boccardi 
et al., 2015b; Jack et al., 2011b; Wolz et al., 2014), their generalizability across acquisition methods 
and centers is still insufficient for their routine application in clinical practice.   
 
This sub-aim can be considered Fully Achieved for vMTA and manual HCV. For automated HCV, this 
aim is considered Partly Achieved.  
 
3.2.3 Phase 2, Secondary aim 2: relationship between pathology and biomarker measurement 
Secondary aim 2 of phase 2 consists of determining the relationship between the biomarker 
measurement and actual pathology.  
Medial temporal lobe atrophy assessed on MRI correlates well with neuropathological findings. In 
post-mortem studies, HCV measured on MRI correlates strongly with histological volume 
measurements (Bobinski et al., 1999). Furthermore, hippocampal atrophy measurements on MRI are 
indicative of Braak neurofibrillary tangle stage at autopsy, even in clinically non-demented subjects 
(Gosche et al., 2002; Jack et al., 2002; Kaur et al., 2014; Whitwell et al., 2008) and HCV on MRI 
correlates strongly with histopathological measures of neuron count and neurofibrillary tangle 
density in the hippocampus (Csernansky et al., 2004; Kril et al., 2004). Good correlations between 
vMTA and Alzheimer pathology at autopsy (Braak staging and plaques and tangles in hippocampus) 
have been demonstrated by a few studies (Barkhof et al., 2007; Burton et al., 2009). However, high 
vMTA scores and decreased HCV are not exclusive to Alzheimer pathology (Barkhof et al., 2007; 
Barnes et al., 2006; Lehmann et al., 2012). Good correlations between Braak stage, neuronal count 
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and HCV on MRI has also been demonstrated for the HarP manual outlining protocol (Apostolova et 
al., 2015).  
 
Several studies have compared visual rating of MTA with volumetric methods and found that vMTA 
ratings correlate well with MRI volumetric measurements (Boutet et al., 2012; Bresciani et al., 2005; 
Clerx et al., 2013; Ridha et al., 2007; Vermersch et al., 1994; Wahlund et al., 1999). 
 
This sub-aim is considered Fully Achieved for vMTA and HCV.  
 
3.2.4 Phase 2, Secondary aim 3: impact of covariates on biomarker measurement in healthy controls 
Phase 2, secondary aim 3 assesses the impact of covariates on the biomarker level in control 
subjects.  
Several factors that influence medial temporal lobe atrophy in cognitively healthy subjects have been 
identified: age, apolipoprotein E (APOE) ɛ4 genotype, vascular risk factors and co-morbid brain 
disease (mostly psychiatric). In studies examining cognitively healthy elderly subjects, a confounding 
effect of preclinical Alzheimer’s disease cannot be ruled out since only very few studies have 
examined pathology verified healthy controls.  
Numerous studies have demonstrated age-related decline in HCV in cognitively healthy adults (Fjell 
et al., 2013; Jack et al., 2015; Lockhart and DeCarli, 2014; van de Pol et al., 2006a). Some studies have 
shown non-linear effects of aging on HCV with increased decline with advancing age (Fjell et al., 
2013; Jack et al., 2015; Raz et al., 2005; Walhovd et al., 2011). Age-related decline in HCV is reflected 
in age-related increase in vMTA scores in cognitively healthy subjects (Cavallin et al., 2012a; 
Scheltens et al., 1992). Older aged subjects are also more prone to have non-Alzheimer pathology 
leading to medial temporal lobe atrophy, such as hippocampal sclerosis (Barkhof et al., 2007). Age-
related decline in HCV is mediated by a protective effect of higher education (Noble et al., 2012). 
Other studies have also shown a protective effect of education on HCV (Schreiber et al., 2016).  
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Various studies report decreased HCV in cognitively healthy subjects with an APOE-ε4 allele 
compared to APOE-ε4 non-carriers (den Heijer et al., 2012; Taylor et al., 2014). However, this effect is 
not undisputed with some researchers finding no effect of APOE-ε4 on cross-sectional HCV (Cherbuin 
et al., 2008; Jack et al., 2015; Okonkwo et al., 2012; Schmidt et al., 1996). A possible explanation for 
these differences could be the inclusion of different study populations, where some of the studies 
that failed to find an effect included younger populations.  
Studies on associations between vascular risk factors, vascular brain lesions and HCV have yielded 
inconsistent results (Lockhart and DeCarli, 2014). In the population-based Rotterdam study, 
researchers found an association between longitudinal hippocampal atrophy rates, vascular white 
matter lesions and diastolic blood pressure (den Heijer et al., 2012). Another large scale study 
showed an effect of smoking and diastolic blood pressure on HCV (Janowitz et al., 2014). Others did 
not find effects of vascular risk factors and vascular white matter hyperintensities on HCV (Gattringer 
et al., 2012).  
Several psychiatric diseases are also associated with decreased HCV in non-demented subjects, such 
as depression (Brown et al., 2014; Geerlings et al., 2012) and post-traumatic stress disorder (Gurvits 
et al., 1996). 
This sub-aim is considered Fully Achieved for vMTA and HCV.  
 
3.2.5 Phase 2, Secondary aim 4: impact of covariates on biomarker measurement in patients with 
Alzheimer’s disease 
Phase 2, secondary aim 4 assesses the impact of covariates on the biomarker measurement in 
subjects with Alzheimer’s disease.  
Many of the same factors that influence medial temporal lobe atrophy in healthy subjects also apply 
to subjects with Alzheimer’s disease. Additionally, several disease-related factors have been shown 
to affect the amount of medial temporal lobe atrophy: age-of-onset, disease stage and clinical 
presentation. A large scale study combining data from the ADNI and AddNeuroMed databases has 
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shown that in subjects with Alzheimer’s dementia, visually rated MTA scores are influenced by age, 
gender and disease duration (Ferreira et al., 2015). Similarly, lower HCV is found with increasing age 
and increasing cognitive impairment in patients with Alzheimer’s disease (Jack et al., 2012; Peng et 
al., 2015; Pol et al., 2006a).  
Compared to the rest of the brain, medial temporal atrophy is most pronounced at an early disease 
stage; at later stages other cortical areas also become more affected (McDonald et al., 2009; Scahill 
et al., 2002; Whitwell et al., 2007). Subjects with early-onset (age ≤ 65 years) Alzheimer’s dementia 
have different atrophy patterns than subjects with late-onset Alzheimer’s dementia. Subjects with 
early-onset Alzheimer’s dementia have more pronounced parietal and precuneal atrophy, whereas 
subjects with late-onset Alzheimer’s disease have more prominent medial temporal atrophy (Cavedo 
et al., 2014; Frisoni et al., 2007; Ishii et al., 2005; Möller et al., 2013). Moreover, early onset-subjects 
have more frequently a non-memory clinical presentation, which is also associated with relative 
hippocampal sparing (Koedam et al., 2010; Mendez et al., 2012; Whitwell et al., 2011).  
In Alzheimer’s disease, carriership of an APOE-ɛ4 allele is associated with decreased volume of 
medial temporal lobe structures (Bigler et al., 2000; Boccardi et al., 2004; Geroldi et al., 1999; 
Hashimoto et al., 2001; Lehtovirta et al., 1995; Manning et al., 2014). This effect may be limited to 
younger subjects: sensitivity of vMTA to detect early-onset Alzheimer’s dementia is high in APOE-ɛ4 
carriers (82%), but only 47% in APOE-ɛ4 non-carriers (Ferreira et al., 2015), whereas in late-onset the 
sensitivity was around 80%, regardless of APOE genotype.  
Taken together, these studies suggest that medial temporal lobe atrophy may not be useful as a 
biomarker for early diagnosis of Alzheimer’s dementia in young onset patients, especially those 
without an APOE-ɛ4 allele or non-memory presentation. 
Studies on the effects of vascular pathology on medial temporal lobe atrophy have inconsistent 
results, with some finding increased medial temporal lobe atrophy associated with white matter 
hyperintensities (Korf et al., 2005; Leeuw et al., 2006), whereas other studies did not find such a 




This sub-aim is considered Fully Achieved for vMTA and HCV.  
 
 
3.3 Phase 3 – Prospective longitudinal repository studies 
In phase 3, the ability of medial temporal lobe atrophy to detect subjects with MCI who will progress 
to Alzheimer’s dementia is assessed based on prospective clinical studies. Evidence is presented from 
studies examining medial temporal lobe atrophy as a predictor for clinical decline from the stage of 
MCI. In this phase, criteria for a positive biomarker test are defined and factors influencing the 
abilities of the biomarker to detect pre-clinical disease are assessed. Additionally, in this phase 
different biomarkers are compared and possibly combined for optimal detection.  
 
3.3.1 Phase 3, Primary aim 1: ability of biomarker to predict progression to Alzheimer’s dementia  
The primary aim of phase 3 is to assess the capacity of the biomarker to detect subjects with MCI 
who will progress to Alzheimer’s dementia. 
Compared to cognitively healthy controls, subjects with MCI have reduced HCV in the following 
order: control > MCI > Alzheimer’s dementia (Frisoni et al., 2008; Pennanen et al., 2004; Shen et al., 
2010; Shi et al., 2009). A considerable amount of studies support the ability of medial temporal lobe 
atrophy to predict progression to dementia from the MCI stage. These studies have recently been 
summarized, resulting in an overall specificity of 75% (CI 67-82) and average sensitivity of 60% (CI 51-
68) for the visual rating of MTA on MRI (Frisoni et al., 2013). Most of the studies reported by Frisoni 
et al. have relatively short clinical follow-up in the order of 1-2 years. deCarli et al. (2007) assessed 
data from a clinical trial with 3 year longitudinal follow-up in 190 subjects with amnestic MCI and 
found an average specificity of 98% and sensitivity of 14% for progression to Alzheimer’s dementia 
with a vMTA cut-off score of ≥ 2 (average of left and right) (DeCarli et al., 2007). With a less stringent 
cut-off (≥1), specificity was 69% and sensitivity 51%. Liu et al. (2013) analyzed MCI subjects from the 
ADNI cohort with three year follow-up and found specificity of 82% and sensitivity of 32% for the 
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prediction of progression to Alzheimer’s dementia with a vMTA cut-off of ≥ 3 on any side (Liu et al., 
2013). Which cut-off scores should be used remains a matter of debate and is elaborated upon in the 
next section.  
 
Specificities and sensitivities of manual HCV for prediction of progression to dementia at the MCI 
stage are on average 81% (CI 73-87) and 58% (CI 47-68) respectively (Frisoni et al., 2013). Specificities 
and sensitivities for automated measurements of HCV are on average 66% (CI 61-71) and 70% (CI 63-
76) respectively (Frisoni et al., 2013). Studies in samples with long follow-up (≥ 3 years) have 
reported similar specificities of 80-87% and sensitivities of 60-67% for manual volumetry (Devanand 
et al., 2007; Fritzsche et al., 2010) and 50% and 83% for automated HCV (Bakkour et al., 2009).  
 
Medial temporal lobe atrophy performs reasonably well in the prediction of cognitive decline from 
the MCI stage but is not specific for Alzheimer’s disease (Barnes et al., 2006; de Souza et al., 2013; 
Harper et al., 2014; van de Pol et al., 2006b; Tam et al., 2005). Other imaging markers such as parietal 
or frontal atrophy may be more useful in differentiating between Alzheimer’s disease and other 
underlying pathologies (Harper et al., 2016, 2015; Koedam et al., 2011; Lehmann et al., 2012; Vemuri 
et al., 2011).  
 
In MCI subjects who progress to Alzheimer-type dementia, vMTA rating is associated with time to 
dementia and can therefore also serve as a prognostic marker (van Rossum et al., 2012a). Similar 
results have been found for volumetric assessments of the hippocampus in MCI (Devanand et al., 
2007) and amyloid positive MCI (Jack et al., 2010b; van Rossum et al., 2012b).  
 
Much evidence has already been gathered on the ability of medial temporal lobe atrophy to predict 
progression to Alzheimer’s dementia. However, to fully complete this aim, sensitivities and 
specificities for progression will also need to be assessed in clinical MCI populations, with longer 
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follow-up. Therefore, we consider this aim Partly Achieved for both vMTA and HCV. Data to fully 
achieve this aim could be readily available from memory clinic samples with standardized use of MRI 
(van der Flier et al., 2014).  
 
3.3.2 Phase 3, Primary aim 2: define criteria for positive biomarker test  
The second primary aim of phase 3 is to define criteria for a positive biomarker test.  
Since there is a considerable influence of age on medial temporal lobe atrophy in both healthy 
subjects and patients with Alzheimer’s dementia, age-related cut-offs for vMTA have been proposed 
(Barkhof et al., 2007; Ferreira et al., 2015; Pereira et al., 2014; Scheltens et al., 1992). A recent large-
scaled study combining data from the ADNI and AddNeuroMed studies examined the effects of 
APOE-ɛ4 on vMTA and demonstrated that early-onset Alzheimer’s disease subjects without APOE-ɛ4 
have lower vMTA sores than APOE-ɛ4 carriers (Pereira et al., 2014). This has led to the proposition of 
age-related cut-offs, stratified by APOE genotype. Using this same dataset, Ferreira and colleagues 
found the highest performance of vMTA to distinguish Alzheimer’s dementia from healthy controls 
when using the following general age-adjusted cut-offs (average scores): 45-74: ≥ 1.5; 75-84: ≥2 and 
85-94: ≥2.5 (sensitivity 80%, specificity 77%). For early-onset (≤65 years) APOE-ɛ4 non-carriers a 
vMTA cut-off ≥2 had better performance (Ferreira et al., 2015). These cut-offs will need to be 
validated for use in prediction of progression from MCI in a prospective clinical setting. 
The proposed cut-offs were derived using average vMTA scores of left and right hemisphere. Other 
researchers have used the highest vMTA score on either side to define abnormality (Scheltens et al, 
1992; Geroldi et al., 2006). Pereira et al. (2014) have examined the performance of different vMTA 
cut-off scores for differentiating patients with Alzheimer’s dementia from healthy controls, including 
cut-offs based on average and highest scores. They found a better performance of age-adjusted 
average cut-off scores compared to age-adjusted highest cut-off scores, especially in the group of 
older patients. Another argument for using average scores is the relatively symmetrical distribution 
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of Alzheimer’s pathology, in contrast to some other neurodegenerative diseases (Chan et al., 2001; 
Boccardi et al., 2003).  
 
For volumetric analysis, several methods to define cut-offs have been used in research settings, 
depending on the intended use and need for either higher sensitivity or specificity (Bartlett et al., 
2012). One strategy that is frequently used involves taking the 95% percentile of a reference 
population, with the implication that everything below this is abnormal. Another commonly used 
method is the creation of covariate-corrected Z-scores, also called W-scores (Jack et al., 1997). W-
scores represent where a hippocampal volume would fall on the normal distribution of healthy 
controls, corrected for covariates. W-scores require the availability of a normative data set. 
Advantages of this method are the possibility to include covariates and the relative robustness of 
derived cut-offs against the use of different measurement algorithms or acquisition methods.  
 
A big challenge in defining universal cut-offs in automated volumetric analysis is the influence of 
image acquisition method (such as scanner type and acquisition protocol) on obtained results 
(Huppertz et al., 2010; Jovicich et al., 2009; Nugent et al., 2013; Wonderlick et al., 2009). Due to the 
large variability in HCV obtained from different automated methods (Guadalupe et al., 2014; Yu et 
al., 2014), universal absolute cut-off points cannot be defined. With the development of the HarP 
(Boccardi et al., 2015a), and of certified labels that may be used to train algorithms for automated 
segmentation (Boccardi et al., 2015b), results from automated volumetry may become more 
consistent between methods in the future.  
 




3.3.3 Phase 3, Secondary aim 1: impact of covariates on biomarker measurement in subjects with 
MCI 
Secondary aim 1 of phase 3 is to explore the impact of covariates on the discriminatory ability of the 
biomarker to predict progression from the MCI stage.  
Few studies have addressed this issue directly. Factors that may impact the ability of medial temporal 
lobe atrophy to predict Alzheimer’s disease at the MCI stage are age, clinical presentation, and APOE 
genotype. In very old subjects there is age-related hippocampal atrophy in healthy subjects as well as 
in Alzheimer’s dementia patients (van de Pol et al., 2006a), which could affect the discriminatory 
ability between normal and abnormal. In early-onset Alzheimer’s dementia, there is less prominent 
involvement of the medial temporal lobe, making this biomarker less suitable for young subjects 
(Frisoni et al., 2007; Möller et al., 2013). Different clinical subtypes of Alzheimer’s dementia are 
associated with specific brain atrophy patterns, which may already be visible in the MCI stage. 
Compared to amnestic MCI, subjects with non-amnestic MCI have relatively spared medial temporal 
lobes (Geroldi et al., 2006; Vos et al., 2013), which reduces the sensitivity of medial temporal lobe 
atrophy for prediction of progression to Alzheimer-type dementia in non-amnestic MCI. 
Using ADNI and AddNeuroMed data, it has been shown that APOE-ɛ4 carriership and early-onset 
disease before the age of 65 affect the performance of vMTA for prediction of clinical progression 
from the MCI stage (Pereira et al., 2014). Further replication of these findings in clinical cohorts and 
extension to volumetric methods are required.  
This secondary aim is considered Partly Achieved for vMTA and HCV.  
 
3.3.4 Phase 3, Secondary aims 2 & 3: comparison and combination of biomarkers 
Secondary aims 2 and 3 of phase 3 are to compare biomarkers and develop algorithms for positivity 
based on combinations of markers.  
Research criteria developed by the National Institute of Aging and the Alzheimer Association (NIA-
AA) have incorporated different stages of likelihood of developing Alzheimer’s dementia based on 
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the combination of amyloid markers (either CSF or PET) and injury markers, such as medial temporal 
atrophy (Sperling et al., 2011). Neuroimaging and CSF markers are currently widely accepted 
biomarkers for Alzheimer’s disease in research settings (Hampel et al., 2008). There is, however, not 
yet enough knowledge about their use in clinical practice. There is no consensus on which 
biomarkers, in what combination and in which order should be used in the work-up of clinical MCI 
patients. Various studies have examined the combination of multiple imaging markers for prediction 
of decline in patients with MCI, which have recently been summarized (Teipel et al., 2015). 
Compared to FDG-PET, measures of hippocampal atrophy seem to be less accurate at predicting 
conversion to Alzheimer’s dementia from MCI (Brück et al., 2013; Chen et al., 2011; Frisoni et al., 
2013; Shaffer et al., 2013; Yuan et al., 2009) but many studies found highest accuracies for a 
combination of biomarkers (Chen et al., 2011; Shaffer et al., 2013). Studies combining information 
from amyloid PET and structural MRI have also reported highest accuracies for combinations of both 
markers rather than a single biomarker (Jack et al., 2008b; Trzepacz et al., 2014). Multiple studies 
have also examined the combined use of CSF and MRI markers for the prediction of clinical 
progression in subjects with MCI. Some have found better prediction for CSF and others for MRI but 
nearly all of them show added benefit of a combination of both (Bouwman et al., 2007; Eckerström 
et al., 2010; Ewers et al., 2012; Galluzzi et al., 2010; Heister et al., 2011; Prestia et al., 2013; Vos et 
al., 2012). Only the study from Bouwman et al. assessed vMTA in a clinical cohort, the others 
assessed HCV in research settings. Differences in findings between the studies may largely be 
explained by use of highly selected samples, different definitions of MCI (or only inclusion of 
amnestic MCI) and variations in methods used for deriving the biomarker measures.  
Some studies have shown that high vMTA scores and decreased HCV may be better predictors of 
time to clinical progression than evidence of amyloid pathology (Jack et al., 2010b; van Rossum et al., 
2012a). Taken together, these studies suggest that different biomarkers provide complementary 
information and that combinations of biomarkers may be needed for accurate prediction of clinical 
progression to Alzheimer’s dementia at the MCI stage. Although recent efforts are focussing on 
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devising algorithms taking into account all available biomarker data to aid in the prediction of 
progression to Alzheimer’s disease in clinical settings (Rhodius-Meester et al., 2015), more research 
is still needed to determine which biomarkers should be used, in which order they should be 
assessed and what to do in the presence of conflicting results. 
 
These sub-aims can be considered Partly Achieved for vMTA and HCV. 
  
3.3.5 Phase 3, Secondary aim 4: biomarker testing interval 
Secondary aim 4 of phase 3 is to determine a biomarker testing interval.  
Progressive hippocampal atrophy is an important imaging finding in Alzheimer’s dementia. Compared 
to cognitively healthy subjects, hippocampal atrophy rates are 2-4 times greater in subjects with 
Alzheimer’s dementia (Barnes et al., 2009; Henneman et al., 2009; Jack et al., 2004; Morra et al., 
2008; Schott et al., 2005). For repeated testing to be useful for diagnosis or prognosis in clinical 
practice, a biomarker should be able to detect changes over short intervals. A visual rating scale is 
not sensitive enough to detect changes over short term follow-up evaluations in the order of one 
year (Ridha et al., 2007). Repeated testing may be valuable in the case hippocampal volumetry 
becomes available for routine clinical application. Hippocampal atrophy rates can be measured 
reliably over a period of one year and some studies have even show that volumetric atrophy rates 
can be measured over periods as short as 6 months (Barnes et al., 2008; Holland et al., 2012; Leung 
et al., 2010; Schuff et al., 2009). Several longitudinal studies have found that increased hippocampal 
atrophy rates are associated with rapid progression to Alzheimer’s dementia in MCI (Leung et al., 
2013; Macdonald et al., 2013; Sluimer et al., 2009; Wang et al., 2009) and may perform better in 
prediction of cognitive decline than baseline hippocampal volumes alone (Henneman et al., 2009; 




This sub-aim is not applicable for vMTA. For HCV this sub-aim can be considered at the stage of 
Preliminary Evidence.  
 
3.4 Phase 4 – Prospective diagnostic studies 
The primary aim of phase 4 is to determine the operating characteristics of the biomarker in a clinical 
setting.  
Most studies that have examined the use of medial temporal atrophy as a predictor for clinical 
progression in subjects with MCI have used highly selected populations in terms of MCI subtypes, 
scan quality and comorbidities and are therefore not generalizable to a memory clinic sample. In 
order to assess the value of medial temporal atrophy as a biomarker for early diagnosis in MCI, it is 
important to also examine clinical populations using methods that are feasible for broad 
implementation. In phase 4 studies, use of the biomarker leads to early diagnosis and the effects on 
patient management and outcome are assessed. We are not aware of any prospective clinical studies 
examining the systematic use of medial temporal atrophy for the prediction of Alzheimer’s disease at 
the MCI stage.  
 
3.4.1 Phase 4, Secondary aim 1: characteristics of disease detected by biomarker in early stage 
Secondary aim 1 of phase 4 assesses the characteristics of the disease identified in an early stage by 
the biomarker in a clinical setting, specifically with regard to potential benefit for the patient incurred 
by early detection.  
This aim is Not Achieved for vMTA and HCV.  
 
 
3.4.2 Phase 4, Secondary aim 2: feasibility of biomarker measurement 
The secondary aim of phase 4 assesses the practical feasibility of implementing the biomarker 




Although not formally assessed, a visual rating of MTA should be feasible in clinical setting. Most 
memory clinics already use imaging in the work-up of memory disorders to exclude other (treatable) 
pathologies such as tumors, vascular damage as well as give direction to underlying 
neurodegenerative pathology such as frontotemporal dementia or progressive supranuclear palsy. 
Tertiary memory clinics or centers associated with a research facility often use standardized MRI 
protocols and may also adopt structured radiology reporting, including a visual rating of MTA (Boutet 
et al., 2012; van der Flier et al., 2014). The application of manual or automated volumetry is still 
distant from implementation in daily clinical practice. To be widely implemented in clinical setting, 
volumetric analysis should be sufficiently standardized, fully automated and easy to use. 
This aim can be considered at the stage of Preliminary Evidence for vMTA and Not Achieved for HCV.  
 
3.4.3 Phase 4, Secondary aim 3: impact on costs and mortality 
The aim is to evaluate the effects of biomarker testing on costs and mortality associated with 
Alzheimer’s disease.  
This aim is Not Achieved for vMTA and HCV.  
 
3.4.4. Phase 4, Secondary aim 4: monitor undetected cases  
This aims includes monitoring disease occurring clinically but not detected by the biomarker testing. 
In order words, this subaim assesses how many subjects with MCI show clinical progression in the 
absence of medial temporal lobe atrophy at baseline and the clinical trajectories of these subjects.  
This aim is Not Achieved for vMTA and HCV.  
 
 
3.5 Phase 5 – Disease control studies 
This final phase addresses whether using biomarkers for early diagnosis reduces the burden of 
Alzheimer’s disease in the general population. There are currently no studies assessing changes in 
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mortality and morbidity, impact on economic costs or overdiagnosis associated with use of medial 
temporal lobe atrophy as diagnostic biomarker for Alzheimer’s disease at the MCI stage.  
This entire phase is considered Not Achieved for vMTA and HCV.  
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4. Conclusions and future perspectives 
In this paper we reviewed the evidence for medial temporal lobe atrophy as a biomarker for 
prediction of Alzheimer’s disease at the MCI stage. We performed this review in the context of a 
wider effort, aiming to accelerate the use of Alzheimer’s disease biomarkers at the predementia 
stage, where differentiating Alzheimer’s disease from normal aging and other causes of cognitive 
impairment is of huge clinical and societal relevance. The effort has borrowed a biomarker validation 
framework developed for oncology biomarkers (Pepe et al., 2001) and ultimately taking inspiration 
from the traditional 4-phase drug development framework. Our working group has adapted the 
oncology framework to the predementia context, highlighting those issues sufficiently investigated 
and those in need of more research. This will allow funders of biomedical research to prioritize 
research topics towards the achievement of the ultimate aim of appropriate, effective and efficient 
use of Alzheimer’s disease biomarkers in the clinic.   
 
In this review, we examined the available evidence for use of medial temporal lobe atrophy for 
prediction of Alzheimer’s disease at the MCI stage in the light of this framework. The first phase has 
been achieved. There is ample evidence to support medial temporal lobe atrophy as a characteristic 
feature of Alzheimer’s disease (phase 1). The second phase, focusing on the ability of the biomarkers 
to distinguish subjects with Alzheimer’s disease from healthy controls has also been achieved for a 
visual rating of MTA. For HCV, phase 2 has not yet been fully completed, with insufficient progress on 
the optimization and standardization of measurement algorithms.  
 
There are still some steps to be taken in the third phase. The current evidence does not support the 
use of vMTA rating or HCV in isolation for the prediction of Alzheimer type dementia at the MCI 
stage. Accuracy for the prediction of progression to Alzheimer’s dementia from the MCI stage has not 
reached clinically acceptable levels with, on average, sensitivities and specificities below 80% (Frisoni 
et al., 2013). It should be noted that most studies have been performed on research samples with 
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short follow-up. Prospective studies on clinical MCI populations with sufficiently long follow-up are 
lacking in the literature. Studies with short follow-up, in the order of 1-2 years, may underestimate 
the predictive ability of the biomarker for clinical progression. The predictive ability of medial 
temporal lobe atrophy is dependent on age, clinical presentation and APOE-ɛ4 genotype (Ferreira et 
al., 2015; Pereira et al., 2014; Vos et al., 2013). However, clear guidelines on cut-offs for clinical 
(sub)populations have not yet been established.  
 
Given the insufficient accuracy of medial temporal lobe atrophy alone for the prediction of 
Alzheimer’s disease at the MCI stage in a clinical setting, phase 4 and phase 5 studies should not be 
undertaken on this single biomarker but rather focus on assessing the impact of combinations of 
biomarkers (Fox et al., 2013; Frisoni et al., 2013). Multiple studies have supported evidence for a 
model in which abnormal amyloid markers are present in early disease; whereas neuronal injury 
markers, such as medial temporal atrophy, may be more useful in predicting advancing pathology 
and thereby serve as a prognostic marker, rather than diagnostic marker (Jack et al., 2010a, 2010b, 
2011c; van Rossum et al., 2012b). Large size clinic-based studies assessing which combinations of 
biomarkers should be used, and in which order and what to do in the case of conflicting biomarker 
results are needed. Related to its potential role as a prognostic marker, HCV may also be valuable as 
a monitor of disease progression and could be used as a biomarker outcome measure in clinical trials 
(Drago et al., 2011; Fox and Freeborough, 1997). For the latter, algorithms will need to have very low 
measurement errors (below 1.5%) to detect effects over a one year follow-up period, as yearly 
hippocampal atrophy rates are in the order of 2.9-5.6% per year for Alzheimer’s disease and 0.3-2.2 
in healthy aging (Frisoni et al., 2010), resulting in an average difference of 3% atrophy per year 
between the groups.  
 
Clinical implementation of a vMTA rating should be achievable, since this is a quick and accessible 
tool, which can be easily learned with adequate training. As structural imaging is already integrated 
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in the work-up of patients with dementia in many clinics, it should be practically feasible to 
implement neuroimaging at the MCI stage as well. Unfortunately, a routine visual assessment of MTA 
is not yet widely adopted, especially in non-specialized clinics (Gardeniers et al., 2015). Adequate 
training may have a significant impact on the performance and application of visual rating scales in 
clinical practice. There might be a role for scientific societies to improve knowledge and know-how 
on visual ratings through the development of guidelines with reference images and training 
programs. Hippocampal volumetry using sophisticated analysis methods, rather than a visual read, 
may ultimately be a more powerful predictor of progression from MCI, but little progress has been 
made towards the integration of these in clinical work streams (Clerx et al., 2013). The EMA has 
approved measurements of HCV for use in clinical trials and similar efforts are being undertaken to 
get approval from the FDA (Hill et al., 2014; Wolz et al., 2014). To be widely adopted in clinical 
setting, volumetric analysis should be fully automated and easy to use, for example through 
implementation on the scanner console.  
 
In this paper, we have discussed the assessment of medial temporal lobe atrophy on MRI. Although 
MRI is the preferred imaging modality in the work-up of dementia, some patients are unable to 
undergo MRI for various reasons (e.g. claustrophobia, pacemaker, unavailability) or MRI is not 
included in national guidelines on dementia care (Falahati et al., 2015). In such cases a high 
resolution CT-scan with multiplanar reconstruction may also be used for the visual assessment of 
MTA, as has been validated by one study (Wattjes et al., 2009). Future research may focus on further 
validating the use of vMTA on CT. Due to the lower contrast resolution, CT has only sporadically been 
used for volumetric measurements (Aguilar et al., 2015).  
 
This review has several limitations. We reviewed the performance of medial temporal lobe atrophy in 
MCI patients, however, the definition of MCI is not homogeneous across different studies. This issue 
is addressed by Cerami et al., in this issue. A further limitation of this study is that, notwithstanding 
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our efforts to be as inclusive as possible, the literature search was not conducted as a formal 
systematic review. A number of PubMed research strings were proposed centrally for the whole 
project; however, the literature databases and some selection criteria for included papers were 
chosen by the authors of each review, who additionally added papers from personal knowledge or 
other papers reference lists. Second, the original Pepe and colleague’s framework was developed to 
screen cancer in asymptomatic populations and has been further adapted to the early diagnosis of 
Alzheimer’s disease in symptomatic memory clinic patients. Future developments of the field of 
Alzheimer’s disease and in drug development may require and allow to extend this framework to 
asymptomatic preclinical patients. Therefore, the nature of this whole effort is liable to change in the 
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To identify leads for potentially useful 
biomarkers and prioritize identified leads. 
Fully achieved 
Pathological studies show early medial temporal lobe 
involvement with neuronal loss in hippocampus. 
Braak and Braak, 1991; 
Braak and Braak, 1996; 
Delacourte et al., 1999; 













To estimate TPR and FPR or ROC curve for 
the assay and to assess its ability to 
distinguish subjects with and without 
disease 
Fully achieved 
vMTA and HCV separate clinical Alzheimer’s dementia 
patients from cognitively healthy subjects with good 
sensitivity and specificity. Few studies have examined 
pathologically verified samples.  
vMTA and HCV are less useful in differential diagnosis of 
dementia patients. 
Frisoni et al., 2013; Likeman et 
al., 2005; Barnes et al., 2006; 
Gosche et al., 2002; Bastos-Leite 
et al., 2007; Galton et al., 2001; 
Haper et al., 2014; van de Pol et 
al., 2006b 
Secondary 1: 
To optimize procedures for performing the 
assay and to assess the reproducibility of 






vMTA has good reproducibility in trained raters. 
Standardized method of collecting MRI (ADNI protocol) 
and manual volumetry (EADC-ADNI harmonized 
segmentation protocol) are sparsely implemented in 
memory clinics. Much variability between different 
automated HCV measurement algorithms.  
Scheltens et al., 1995; Tolboom 
et al., 2010; Boutet et al., 2012; 
Cavallin et al. 2012b; Jack et al., 
2008a; Boccardi et al., 2015a; 
Guadalupe et al., 2014; Yu et al., 
2014 
Secondary 2: 
To determine the relationship between 
biomarker tissue measurements made on 
tissue (phase 1) and the biomarker 
measurements made on the noninvasive 
clinical specimen (phase 2) 
Fully achieved 
Good correlation between hippocampal size on MR and 
histological measurements and severity of 
neurodegenerative changes on pathology. 
Bobinski et al., 1999; Gosche et 
al., 2002; Jack et al. 2002; Kaur et 
al., 2014; Whitwell et al., 2008; 
Csernansky et al., 2004; Kril et al., 
2004; Barkhof et al., 2007; Burton 
et al., 2009; Apostolova et al., 
2015 
Secondary 3: 
To assess factors associated with 
biomarker status or level in control 
subjects. If such factors affect the 
biomarker, thresholds for test positivity 
may need to be defined separately for 
target subpopulations. 
Fully achieved 
Well-known age-associated HCV loss (higher vMTA scores). 
Amount of atrophy also dependent on APOE-ɛ4 
carriership, vascular pathology, education; impact of these 
latter variables only relevant for volumetry, not for visual 
rating. 
Fjell et al., 2013; Jack et al., 2015; 
Lockhart and DeCarli, 2014; den 
Heijer et al., 2012; Taylor et al., 
2014; Cherbuin et al., 2008; 
Janowitz et al., 2014; Gattringer 




To assess factors associated with 
biomarker status or level in diseased 
subjects—in particular, disease 
characteristics. 
Fully achieved 
Similar as for healthy subjects: influence of age, APOE-ɛ4, 
vascular pathology. Additionally, clinical presentation is 
relevant: subjects with early onset and primary non-
memory presentation have relatively spared medial 
temporal lobes. 
Ferreira et al., 2015; Jack et al., 
2012; Peng et al., 2015; Cavedo 
et al., 2014; Möller et al., 2013; 
Ishii et al., 2005; Koedam et al., 
2010; Mendez et al., 2012; 
Whitwell et al. 2011; Bigler et al., 
2000; Boccardi et al., 2004; 
Geroldi et al., 1999; Hashimoto et 
al., 2001; Lehtovirta et al., 1995; 







ability of the 
biomarker to 
detect the 
disease in its 
early phase 
Primary 1: 
To evaluate the capacity of the biomarker 
to detect the earliest disease stages 
Partly 
achieved 
No evidence in clinical MCI cohorts with long follow-up. In 
research populations or clinical populations with shorter 
follow-up, there is a reasonably good specificity but lower 
sensitivity to predict clinical progression in subjects with 
MCI. 
Frisoni et al., 2013; deCarli et al., 
2007; Liu et al., 2013; Devanand 
et al., 2007; Fritzsche et al., 2010; 
Bakkour et al., 2009  
Primary 2: 
To define criteria for a biomarker positive 







Age and APOE-ɛ4 related cut-offs for vMTA based on 
discrimination of controls from Alzheimer’s dementia. 
Validation needed in clinical MCI cohorts.  
No universal cut-offs for volumetry; substantial variability 
between acquisition protocols and measurement 
algorithms.  
Barkhof et al., 2007; Ferreira et 
al., 2015; Pereira et al., 2014; 
Jack et al, 1997 
Secondary 1: 
To explore the impact of covariates on the 
discriminatory abilities of the biomarker 
before clinical diagnosis. 
Partly 
achieved 
Impact of age, APOE-ɛ4 genotype and clinical 
presentation. 
Pereira et al., 2014; Geroldi et al., 
2006; Vos et al., 2013 
Secondary 2: 
To compare markers with a view to 




Various studies on association of two or more core 
biomarkers; usually best predictive value for combination 
of amyloid marker with an injury marker. 
Teipel et al., 2015; Brück et al., 
2013; Chen et al., 2011; Shaffer 
et al., 2013; Yuan et al., 2009; 
Jack et al., 2008b; Trzepacz et al., 
2014; Bouwman et al., 2007; 
Eckerström et al., 2010; Ewers et 
al., 2012; Galluzzi et al., 2010; 
Heister et al., 2011; Prestia et al., 
2013; Vos et al., 2012; Rhodius-
Meester et al., 2015 
Secondary 3: 
To develop algorithms for positivity based 




To determine a biomarker testing interval 







Not applicable for vMTA. Preliminary evidence on added 
value of hippocampal atrophy rates for predicting clinical 
progression to Alzheimer’s dementia in patients with MCI.  
Ridha et al., 2007; Leung et al., 
2010, 2013; Macdonald et al., 
2013; Henneman et al., 2009; 
McEvoy et al., 2011; Holland et 
al., 2012; Sluimer et al., 2009; 
















To determine the operating characteristics 
of the biomarker-based test in a relevant 
population by determining the detection 
rate and the false referral rate. Studies at 
this stage involve testing people and lead 
to diagnosis and treatment. 
Not achieved  
 
Secondary 1: 
To describe the characteristics of disease 
detected by the biomarker test—in 
particular, with regard to the potential 
benefit incurred by early detection. 
Not achieved  
 
Secondary 2: 
To assess the practical feasibility of 
implementing the diagnostic program and 
compliance of test-positive subjects with 






Imaging integrated in standard work-up for dementia 
patients in most memory clinics. vMTA and quantitative 
assessment not yet widely implemented. 
Boutet et al., 2012; van der Flier 
et al., 2014 
Secondary 3: 
To make preliminary assessments of the 
effects of biomarker testing on costs and 
mortality associated with the disease. 
Not achieved  
 
Secondary 4: 
To monitor disease occurring clinically but 
not detected by the biomarker testing 
protocol. 














To estimate the reductions in disease-
associated mortality, morbidity, and 
disability afforded by biomarker testing. 
Not achieved  
 
Secondary 1: 
To obtain information about the costs of 
biomarker testing and treatment and the 
cost per life saved or per quality-adjusted 
life year 





Table 1: Available or required evidence indicating full, partial or lack of achievement of the phases adapted from the oncology framework (Pepe et al., 2001) 
for visual rating of medial temporal lobe atrophy (vMTA) and hippocampal volume (HCV). 
costs 
 Secondary 2: 
To evaluate compliance with testing and 
work-up in a diverse range of settings. 
Not achieved  
 
Secondary 3: 
To compare different biomarker testing 
protocols and/or to compare different 
approaches to treating test positive 
subjects in regard to effects on mortality 
and costs. 




Figure 1: Synopsis of the maturity of a visual rating of medial temporal lobe atrophy (upper panel) and hippocampal volumetry (lower panel) as borrowed 
from the oncology framework (Pepe et al., 2001). AD: Alzheimer’s disease; HC: healthy controls; HCV: hippocampal volume; MCI: mild cognitive impairment; 
vMTA: visual rating of medial temporal lobe atrophy
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Supplementary table 1: 
PhPhasP Phase Aim Aim-specific key words string  
Phase 1: preclinical 
exploratory studies 
Primary aim: To identify leads for potentially useful biomarkers 
and prioritize identified leads. 
NO STRINGS USED 
Phase 2: clinical 
assay development 
for clinical disease 
Primary aim: To estimate TPR and FPR or ROC curve for the assay 
and to assess its ability to distinguish subjects with and without 
disease.  
(“accuracy” OR “sensitivity” OR “specificity” OR “ROC” OR “predictive value”) AND (a) 
AND (b) AND (d).  
 Secondary aim 1: To optimize procedures for performing the assay 
and to assess the reproducibility of the assay within and between 
laboratories. 
(“standardization” OR “visual” OR “measure” OR “assessment” OR “reading” OR 
“quantification” AND (“reproducibility” OR “reliability” OR “agreement”) AND (a) AND (d) 
 Secondary aim 2: To determine the relationship between 
biomarker tissue measurements made on tissue (phase 1) and the 
biomarker measurements made on the noninvasive clinical 
specimen (phase 2).  
("autopsy" OR “autoptic” OR “patholog*” OR “neuropatholog*” OR “istopathol*”) AND 
MRI AND (a) AND (d)  
 Secondary aim 3: To assess factors (e.g. sex, age, etc.), associated 
with biomarker status or level in control subjects. If such factors 
affect the biomarker, thresholds for test positivity may need to be 
defined separately for target subpopulations.  
- (“APOE” OR “Apolipoprotein E”) AND (b) AND (d) 
- (“vascular risk factors” OR “white matter hyperintensities) AND (b) AND (d) 
 
 Secondary aim 4: To assess factors associated with biomarker 
status or level in diseased subjects—in particular, disease 
characteristics. 
- (“APOE” OR “Apolipoprotein E”) AND (a) AND (d) 
- (“vascular risk factors” OR “white matter hyperintensities) AND (a) AND (d) 
- (“early-onset” OR “late-onset”) AND (a) AND (d) 
Phase 3: Prospective 
repository studies 
Primary aim: To evaluate the capacity of biomarkers to detect pre-
clinical disease and define criteria for a positive biomarker test in 
preparation for phase 4.  
- ("follow-up" OR "followup" OR "conversion" OR "progression" OR “decline” OR 
"predict*") AND MRI AND (“visual” OR “rating”) AND (c) AND (d)  
- (“cut-off*” OR “cut-point”) AND (d)  
 Secondary aim 1:To explore the impact of covariates on the 
discriminatory abilities of the biomarker before clinical diagnosis.  
- (“APOE” OR “Apolipoprotein E”) AND (c) AND (d) 
- (“amnestic” OR “non-amnestic”) AND (c) AND (d) 
 
 Secondary aim 2: To compare markers with a view to selecting 
those that are most promising.  
("follow-up" OR "followup" OR "conversion" OR "progression" OR “decline” OR 
"predict*") AND (“combinat*” OR “associat*” OR “compar*”) AND MRI AND (a) AND (c)  
 Secondary aim 3:To develop algorithms for positivity based on 
combinations of markers.  
("follow-up" OR "followup" OR "conversion" OR "progression" OR “decline” OR 
"predict*") AND (“combinat*” OR “associat*” OR “compar*”) AND MRI AND (a) AND (c) 
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 Secondary aim 4:To determine a biomarker testing interval for 
phase 4 if repeated testing is of interest.  
("atrophy rates”) AND (a) AND (c) AND (d) 
Phase 4: Prospective 
Diagnostic Studies 
Primary aim: To determine the operating characteristics of the 
biomarker-based test in a relevant population by determining the 
detection rate and the false referral rate. Studies at this stage 
involve testing people and lead to diagnosis and treatment. 
(“diagnosis” OR “treatment”) AND (a) AND (c) AND (d) 
 Secondary aim 1:To describe the characteristics of disease 
detected by the biomarker test—in particular, with regard to the 
potential benefit incurred by early detection. 
(“clinical diagnosis” OR “treatment” OR “memory clinic”) AND (“benefits” OR “outcome” 
OR “improve*”) AND (a) AND (c) AND (d) 
 Secondary aim 2:To assess the practical feasibility of implementing 
the case finding program and compliance of test-positive subjects 
with work-up and treatment recommendations. 
(“clinical diagnosis” OR “treatment” OR “memory clinic”) AND (“benefit*” OR 
“compliance” OR “mortality” OR “morbidity” OR “QoL” OR “quality of life”) AND (a) AND 
(d) 
 Secondary aim 3:To make preliminary assessments of the effects 
of biomarker testing on costs and mortality associated with the 
disease. 
(“clinical diagnosis” OR “treatment” OR “memory clinic”) AND (“benefit*” OR 
“compliance” OR “mortality” OR “morbidity” OR “QoL” OR “quality of life” OR “cost*”) 
AND (a) AND (d) 
 Secondary aim 4:To monitor disease occurring clinically but not 
detected by the biomarker testing protocol. 
(“clinical diagnosis” OR “memory clinic” OR “criteria” OR “recommendation*”) AND 
(“accuracy” OR “sensitivity” OR “specificity” OR “ROC” OR “predictive value” OR 
“concordance” OR “confirm” OR “negative detection rate” OR “negative referral rate” OR 
“false negative rate”) AND (a) AND (d) 
Phase 5: Disease 
Control Studies 
Primary aim: To estimate the reductions in disease-associated 
mortality, morbidity, and disability afforded by biomarker testing. 
(“diagnosis” OR “detection”) AND (“benefit*” OR “compliance” OR “mortality” OR 
“morbidity” OR “QoL” OR “quality of life” OR “financial impact” OR “cost*” OR 
“effectiveness”) AND (a) AND (d) 
 Secondary aim 1: To obtain information about the costs of 
biomarker testing and treatment and the cost per life saved or per 
quality-adjusted life year 
(“diagnosis” OR “detection”) AND (“benefit*” OR “compliance” OR “mortality” OR 
“morbidity” OR “QoL” OR “quality of life” OR “outcome*”) AND (“financial impact” OR 
“cost*” OR “effectiveness”) AND (a) AND (d) 
 Secondary aim 2: To evaluate compliance with testing and work-up 
in a diverse range of settings. 
(“diagnosis” OR “treatment”) AND (“benefit*” OR “compliance” OR “mortality” OR 
“morbidity” OR “QoL” OR “quality of life”) AND (“primary care” OR “second level” OR 
“third level”) AND “memory clinic” AND “cost*” AND (a) AND (d) 
 Secondary aim 3:To compare different biomarker testing protocols 
and/or to compare different approaches to treating test positive 
subjects in regard to effects on mortality and costs. 
“diagnosis” OR “treatment”) AND (“protocol” OR “recommendation*” OR “criteria”) AND 
(“benefit*” OR “compliance” OR “mortality” OR “morbidity” OR “QoL” OR “quality of 
life”) AND (“financial impact” OR “cost*” OR “effectiveness”) AND (a) AND (d) 
 
(a) (“Alzheimer*”) 
(b) ("Healthy controls" OR "Cognitively normal" OR "controls" OR "normal") 
(c) (“MCI” OR “mild cognitive impairment” OR ”prodromal”) 
(d)  (“MTA” OR “medial temporal” OR “hippocamp*”) 
